Coenzyme Q10 ( DrugBank: Coenzyme Q10 )
11 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 1 |
5 | Progressive supranuclear palsy | 4 |
6 | Parkinson disease | 5 |
8 | Huntington disease | 2 |
10 | Charcot-Marie-Tooth disease | 1 |
18 | Spinocerebellar degeneration | 1 |
46 | Malignant rheumatoid arthritis | 1 |
57 | Idiopathic dilated cardiomyopathy | 1 |
113 | Muscular dystrophy | 3 |
214 | Pulmonary atresia with ventricular septum defect | 1 |
215 | Tetralogy of Fallot | 1 |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00243932 (ClinicalTrials.gov) | April 2005 | 24/10/2005 | Clinical Trial of High Dose CoQ10 in ALS | Clinical Trial of High Dose CoQ10 in ALS | Amyotrophic Lateral Sclerosis;Lou Gehrig's Disease | Drug: coenzyme Q10;Drug: Placebo | Columbia University | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | 21 Years | 85 Years | All | 185 | Phase 2 | United States |
5. Progressive supranuclear palsy
Clinical trials : 89 / Drugs : 107 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00382824 (ClinicalTrials.gov) | September 2006 | 28/9/2006 | Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) | Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP): A Multicenter, Randomized, Placebo-controlled, Double Blind Study | Progressive Supranuclear Palsy | Dietary Supplement: Coenzyme Q10;Other: Placebo | Lahey Clinic | NULL | Completed | 30 Years | N/A | All | 61 | N/A | United States |
2 | NCT00328874 (ClinicalTrials.gov) | May 2006 | 21/5/2006 | Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy | Mono-center, Prospective, Double-blind, Placebo-controlled, Randomized Clinical Phase IIa Trial to Assess the Safety, Tolerability, and Immediate Biological Effects of Coenzyme Q10 - nanoQuinon® in Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: Coenzyme Q10 | German Parkinson Study Group (GPS) | MSE Pharmazeutika GmbH, Louisenstr.114D-61348 Bad Homburg, Germany;Pitzer Stiftung;Philipps University Marburg Medical Center | Completed | 40 Years | 85 Years | All | 20 | Phase 2 | Germany |
3 | EUCTR2005-000574-40-DE (EUCTR) | 24/04/2006 | 24/01/2006 | Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/A | Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/A | PSP is a sporadic neurodegenerative disorder resulting in a Parkinson syndrome with postural instability, oculomotor deficits, and cognitive decline. With an average annual incidence of 5.3 / 100000 and an age-adjusted prevalence of 6.4 / 100000, PSP is as common as motor-neuron disease. The progression of PSP is rapid and the median survival after onset of symptoms is 5-10 years. Presently, there is no known effective symptomatic or neuroprotective therapy for PSP. | Product Name: Coenzym Q10 Nanodispersion Product Code: ASK Nr. 21972 INN or Proposed INN: Ubidecarenon Other descriptive name: Coenzym Q10, Ubiquinon, Ubichinon | Kompetenznetz Parkinson e.V. | NULL | Not Recruiting | Female: yes Male: yes | 30 | Germany | |||
4 | NCT00532571 (ClinicalTrials.gov) | January 2004 | 18/9/2007 | Effects of Coenzyme Q10 in PSP and CBD | Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study | Progressive Supranuclear Palsy;Neurological Disorders | Drug: CoQ10 | Lahey Clinic | NULL | Completed | 40 Years | N/A | All | Phase 2/Phase 3 | United States |
6. Parkinson disease
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-UMIN000019090 | 2015/11/04 | 01/11/2015 | Reduced form of CoenzymeQ10 for Parkinson's disease - open trial of dose finding test and combination with hydrogen water | Reduced form of CoenzymeQ10 for Parkinson's disease - open trial of dose finding test and combination with hydrogen water - Dose finding test of reduced form of Coenzyme Q10 for Parkinson's disease | Parkinson's disease | reduced form of CoQ10 300mg 16weeks reduced form of CoQ10 600mg 16weeks reduced form of CoQ10 600mg 16weeks hydrogen water 500ml(Suisosui 7.0) 16weeks | Juntendo University Koshigaya Hospital | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 45 | Not selected | Japan |
2 | NCT01892176 (ClinicalTrials.gov) | June 2012 | 30/6/2013 | Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease | Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease | Parkinson Disease | Dietary Supplement: coenzyme q10 | National University Hospital, Singapore | NULL | Completed | 21 Months | N/A | Both | 20 | Phase 2/Phase 3 | Singapore |
3 | NCT00740714 (ClinicalTrials.gov) | December 2008 | 22/8/2008 | Effects of Coenzyme Q10 (CoQ) in Parkinson Disease | Effects of Coenzyme Q10 in Parkinson Disease - Phase III | Parkinson Disease | Drug: Coenzyme Q10 with vitamin E;Drug: placebo with vitamin E | Weill Medical College of Cornell University | National Institute of Neurological Disorders and Stroke (NINDS);University of Rochester | Terminated | 30 Years | N/A | All | 600 | Phase 3 | United States;Canada |
4 | NCT00180037 (ClinicalTrials.gov) | September 2003 | 9/9/2005 | Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease | Multicenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's Disease | Parkinson's Disease | Drug: Coenzyme Q10 Nanodispersion (Nanoquinone);Drug: Placebo | Technische Universität Dresden | Deutsche Parkinson-Vereinigung e.V.;MSE Pharmazeutika GmbH, Bad Homburg | Completed | 40 Years | 75 Years | Both | 132 | Phase 3 | Germany |
5 | NCT00004731 (ClinicalTrials.gov) | September 1998 | 25/2/2000 | Parkinson's Disease Treatment With Coenzyme Q10 | Effects of Coenzyme Q10 in Early Parkinson's Disease | Parkinson's Disease | Drug: Coenzyme Q10 | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | 30 Years | N/A | Both | Phase 2 | United States |
8. Huntington disease
Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00920699 (ClinicalTrials.gov) | February 2010 | 9/6/2009 | Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL) | A Multi-Center, Double-Blind, Randomized, Parallel Group Tolerability Study of Coenzyme Q10 (UbiquinonE)in PRE-manifest Huntington's Disease | Huntington's Disease | Drug: CoQ10 | Johns Hopkins University | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | 18 Years | N/A | All | 90 | Phase 2 | United States |
2 | NCT00608881 (ClinicalTrials.gov) | March 2008 | 4/2/2008 | Coenzyme Q10 in Huntington's Disease (HD) | Coenzyme Q10 in Huntington's Disease (HD) | Huntington's Disease | Drug: coenzyme Q10;Other: placebo | Massachusetts General Hospital | National Institute of Neurological Disorders and Stroke (NINDS);University of Rochester | Terminated | 16 Years | N/A | All | 609 | Phase 3 | United States;Australia;Canada |
10. Charcot-Marie-Tooth disease
Clinical trials : 41 / Drugs : 46 - (DrugBank : 9) / Drug target genes : 11 - Drug target pathways : 15
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00541164 (ClinicalTrials.gov) | September 2007 | 9/10/2007 | Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease | Effects of Coenzyme Q10 (CoQ10) on Subjects With Charcot-Marie-Tooth Disease (CMT):A Double Blind, Randomized, Controlled Trial With an Open Label Follow-up Study | Charcot Marie Tooth Disease | Drug: Coenzyme Q10;Dietary Supplement: Coenzyme Q10 | Memorial Medical Center | Department of Defense | Completed | 18 Years | 75 Years | Both | 23 | Phase 1/Phase 2 | United States |
18. Spinocerebellar degeneration
Clinical trials : 76 / Drugs : 98 - (DrugBank : 31) / Drug target genes : 44 - Drug target pathways : 65
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-UMIN000031788 | 2018/06/01 | 01/04/2018 | coenzymeQ10 for Autosomal recessive spinocerebellar ataxia type II | coenzymeQ10 for Autosomal recessive spinocerebellar ataxia type II - coenzymeQ10 for Autosomal recessive spinocerebellar ataxia type II | Autosomal recessive spinocerebellar ataxia type II | high dose of coenzyme Q10 | Department of Neurology, Tokushima University, Japan | NULL | Complete: follow-up complete | 50years-old | 100years-old | Male and Female | 1 | Not selected | Japan |
46. Malignant rheumatoid arthritis
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR-IPR-17010325 | 2017-01-31 | 2017-01-04 | The efficacy and safety of Metformin combined with coenzyme Q10 in refractory rheumatoid arthritis: A multi-center randomized controlled trial | The efficacy and safety of Metformin combined with coenzyme Q10 in refractory rheumatoid arthritis: A multi-center randomized controlled trial | rheumatic disease;M05.901 | Metformin Group:Metformin combined Glucocorticoids and DMARDs;Non-Metformin Group:Glucocorticoids and DMARDs;Metformin combined with Coenzyme Q10 Group:Metformin and Coenzyme Q10 combined Glucocorticoids and DMARDs; | the Second Hospital of Shanxi Medical University | NULL | Pending | 18 | 65 | Both | Metformin Group:100;Non-Metformin Group:100;Metformin combined with Coenzyme Q10 Group:100; | China |
57. Idiopathic dilated cardiomyopathy
Clinical trials : 11 / Drugs : 23 - (DrugBank : 12) / Drug target genes : 9 - Drug target pathways : 35
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02115581 (ClinicalTrials.gov) | September 2006 | 22/12/2008 | Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy | Effect of Coenzyme Q10 (Ubiquinone) Supplementation on Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy.A Randomised Clinical Trial | Dilated Cardiomyopathy | Drug: Coenzyme Q10;Drug: Placebo | University of Tehran | NULL | Completed | 6 Months | 18 Years | All | 38 | Phase 4 | Iran, Islamic Republic of |
113. Muscular dystrophy
Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01126697 (ClinicalTrials.gov) | February 2010 | 18/5/2010 | Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies | PITT0908: Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies | Duchenne Muscular Dystrophy;Becker Muscular Dystrophy;Limb Girdle Muscular Dystrophy | Drug: Coenzyme Q10 and Lisinopril | Cooperative International Neuromuscular Research Group | United States Department of Defense | Completed | 8 Years | N/A | All | 63 | Phase 2/Phase 3 | United States;Canada;Japan |
2 | NCT00308113 (ClinicalTrials.gov) | April 2007 | 27/3/2006 | CoQ10 and Prednisone in Non-Ambulatory DMD | PITT0503: Clinical Trial of Coenzyme Q10 and Prednisone in Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Drug: Prednisone;Dietary Supplement: Coenzyme Q10 | Cooperative International Neuromuscular Research Group | United States Department of Defense | Terminated | 10 Years | 18 Years | Male | 3 | Phase 3 | United States;Australia;Puerto Rico |
3 | NCT00033189 (ClinicalTrials.gov) | September 2001 | 8/4/2002 | An Open-label Pilot Study of Coenzyme Q10 in Steroid-Treated Duchenne Muscular Dystrophy | Muscular Dystrophy, Duchenne | Drug: Coenzyme Q10 | Cooperative International Neuromuscular Research Group | NULL | Completed | 5 Years | 11 Years | Male | 15 | Phase 2 | United States |
214. Pulmonary atresia with ventricular septum defect
Clinical trials : 2 / Drugs : 4 - (DrugBank : 4) / Drug target gene : 0 - Drug target pathway : 0
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR1900025513 | 2019-09-01 | 2019-08-31 | The safety and efficacy of preoperative oral supplementation of coenzyme Q10 in improving postoperative cardiac function in children with tetralogy of fallot (pulmonary atresia): a preliminary study | The safety and efficacy of preoperative oral supplementation of coenzyme Q10 in improving postoperative cardiac function in children with tetralogy of fallot (pulmonary atresia): a preliminary study | tetralogy of fallot (pulmonary atresia) | 01:N/A ;02:Oral coenzyme Q10, 2.5mg, t.i.d.;03:Oral coenzyme Q10, 5mg, t.i.d.;04:Oral coenzyme Q10, 10mg, t.i.d.;05:Oral coenzyme Q10, 20mg, t.i.d.; | Fuwai Central China Cardiovascualr Hospital | NULL | Pending | 0 | 2 | Both | 01:8;02:8;03:8;04:8;05:8; | China |
215. Tetralogy of Fallot
Clinical trials : 18 / Drugs : 26 - (DrugBank : 14) / Drug target genes : 13 - Drug target pathways : 45
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR1900025513 | 2019-09-01 | 2019-08-31 | The safety and efficacy of preoperative oral supplementation of coenzyme Q10 in improving postoperative cardiac function in children with tetralogy of fallot (pulmonary atresia): a preliminary study | The safety and efficacy of preoperative oral supplementation of coenzyme Q10 in improving postoperative cardiac function in children with tetralogy of fallot (pulmonary atresia): a preliminary study | tetralogy of fallot (pulmonary atresia) | 01:N/A ;02:Oral coenzyme Q10, 2.5mg, t.i.d.;03:Oral coenzyme Q10, 5mg, t.i.d.;04:Oral coenzyme Q10, 10mg, t.i.d.;05:Oral coenzyme Q10, 20mg, t.i.d.; | Fuwai Central China Cardiovascualr Hospital | NULL | Pending | 0 | 2 | Both | 01:8;02:8;03:8;04:8;05:8; | China |